Hong Kong’s Insilico plans secondary listing in Abu Dhabi

Hong Kong-listed Insilico Medicine Cayman TopCo is reportedly planning a secondary listing in Abu Dhabi.

The biotech company, which was listed on the Hong Kong bourse in December, has held early talks about a secondary listing on the Abu Dhabi Securities Exchange (ADX) this year, Bloomberg reported, citing unidentified sources.

Insilico will become the first company outside the GCC to list shares on a regional exchange if the listing goes ahead.

A direct listing is initially possible, though Insilico may opt to raise additional capital, the report said.

Further reading:

• Abu Dhabi ‘can win global healthcare marathon’
• Bahrain strikes AI deal to create $1bn biotech assets
• Alpha Dhabi pays $545m dividend for 2025

Several Abu Dhabi-based investors participated in the biotech company’s initial public offering, which raised $337 million in December.

In April, Insilico, which uses artificial intelligence for drug discovery, announced its first preclinical candidate in the UAE.

In September 2025, the ADX signed an agreement with Hong Kong Exchanges and Clearing Limited to deepen cooperation by exploring dual listings, cross-border financing and mechanisms to facilitate investment.